Study of the Effect of GM-CSF on Macrophages in Ependymoma

Status Completed

Clinical Trial Summary

This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma

Clinical Trial Description

To study whether Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) increases macrophage infiltration in children with ependymoma (EPN) who are to have planned surgery as a standard procedure for incomplete resection or recurrent tumor. To correlate the extent of macrophage infiltration with other immune markers of the tumor at subsequent surgery with outcome. This is intended as a pilot protocol with the potential to be incorporated in the next COG (Children's Oncology Group) national ependymoma studies. Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). Registration of all participants must occur before any study-related procedures. Staff will be available to register participants Monday thru Friday, from 8:00 AM to 5:00 PM Mountain Standard Time. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04408092
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Completed
Phase	Early Phase 1
Start date	June 25, 2013
Completion date	July 21, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00994071` - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	Phase 1
Completed	`NCT01171469` - Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor	Phase 1
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Recruiting	`NCT04541082` - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Phase 1
Completed	`NCT02502708` - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	Phase 1
Recruiting	`NCT04049669` - Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG	Phase 2
Recruiting	`NCT06038760` - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Completed	`NCT03043391` - Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	Phase 1
Active, not recruiting	`NCT03095248` - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Phase 2
Active, not recruiting	`NCT02125786` - A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma	Phase 2
Active, not recruiting	`NCT01096368` - Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma	Phase 3
Terminated	`NCT01247922` - Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205	Phase 2
Completed	`NCT03900689` - Social Determinants of Health in Glioblastoma Population
Recruiting	`NCT04661384` - Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma	Phase 1
Active, not recruiting	`NCT03434262` - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	Phase 1
Recruiting	`NCT05259605` - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Terminated	`NCT01836549` - Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors	Phase 2
Active, not recruiting	`NCT03638167` - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	Phase 1